



Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

I, **Alberto Martire**

Organisation/Company:

Country:

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

1.1 Employment

No interest declared

1.2 Consultancy

No interest declared

1.3 Strategic advisory role

No interest declared

1.4 Financial interests

No interest declared

1.5 Principal investigator

No interest declared

1.6 Investigator

No interest declared

1.7 Grant / Funding to organisation /institution

No interest declared

1.8 Close family member interest

No interest declared

1.9 Repurposing of a medicinal product

No interest declared

1.10 Any other interests or facts

Since January 2014: I have been Principal Investigator of the following project: GR_2011_02348150 "Adenosine A2A receptors as a possible therapeutic target in Niemann_Pick type C disease" (Grant of 342.000,00 Euros from Italian Ministry of Health for 2014_2015_2016, extended until November 2018). Since October 2018: I have been Principal Investigator of the following project: "Characterization of Adenosine Receptors in a Mouse Model of Fragile X Syndrome" (Grant of 90.000,00 USD from FRAXA Research Foundation for 2018_2021). FRAXA Research Foundation is one of the main US Organizations representing individuals, and related families, with Fragile X Syndrome. I cannot rule out that such a Foundation could be supported also by Pharmaceutical companies. Furthermore, the basic research/preclinical project that we are carrying on with FRAXA funds involves the use of a drug (KW6002 from Kyowa, Japan) that is already approved in Japan and US for the treatment of Parkinson's disease. Anyway, we have not any relationship with the Company and we are buying the drug with our own funds, since it is commercially available. Since October 2021: I have been a collaborator of the following project: "Characterization of microglia transcriptional profile in fmr1ko mice model" (Grant of 45.000,00 USD from FRAXA Research Foundation for 2021_2022). FRAXA Research Foundation is one of the main US Organizations representing individuals, and related families, with Fragile X Syndrome. I cannot rule out that such a Foundation could be supported also by Pharmaceutical companies. Furthermore, the basic research/preclinical project that we are carrying on with FRAXA funds involves the use of a drug (Vorinostat) that is already approved in US for the treatment of cutaneous T cell lymphoma . Anyway, we have not any relationship with pharmaceutical companies and we are buying the drug with our own funds, since it is commercially available. Since October 2022: I am currently the PI of the following project: "Exosomes as a source of therapeutic biomarkers in experimental models of Fragile X Syndrome" (Grant of 50.000,00 USD from FRAXA Research Foundation for 2022_2023). FRAXA Research Foundation is one of the main US Organizations representing individuals, and related families, with Fragile X Syndrome. I cannot rule out that such a Foundation could be supported also by Pharmaceutical companies. However, the project that will be carried on with FRAXA funding involves the use of a drug (istradefylline or KW6002 from Kyowa, Japan) that is already approved in Japan and US for the treatment of Parkinson's disease. However, we have not any relationship with pharmaceutical companies and we will buy the drug with our own funds, since it is commercially available. I cannot rule out that some of my colleagues in my institution provide consultancy advice to pharmaceutical companies, but, anyway, I am not directly or indirectly involved in the provision of such advice.

1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No interest declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

No interest declared

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.

- Not to disclose (or authorise any other person to disclose) in any way to any third party ¹ any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.

Full Name:	Alberto Martire
Date:	2023-03-22

For definitions of activities etc, refer to the policy on handling of competing interests.